ArticleClinical, cosmetic and investigational dermatology2009
Update on terbinafine with a focus on dermatophytoses.
Article in Clinical, cosmetic and investigational dermatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 66 citations in OpenAlex.
- Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study.Indian journal of pharmacologyTrial
- In Vitro Antifungal Activity of Octenidine Against Emerging Dermatophyte Species.Mycopathologia · 2026Article
- Systemic use of terbinafine in veterinary medicine: A review of pharmacokinetic studies.Veterinary research communications · 2026Review
- Clinical and Mycological Profiles of Chronic and Recalcitrant Dermatophytosis: Türkiye, 2022-2024.Mycopathologia · 2026Article
- Emerging antifungal resistance inEmerging microbes & infections · 2025Article
- Infection patterns of scabies and tinea between inland and resettled indigenous Negrito communities in Peninsular Malaysia.PLoS neglected tropical diseases · 2024Article
- Catalase Deactivation Increases Dermatophyte Sensitivity to ROS Sources.Journal of fungi (Basel, Switzerland) · 2024Article
- High Prevalence of Terbinafine Resistance Among Trichophyton mentagrophytes/T. interdigitale Species Complex, a Cross-Sectional Study from 2021 to 2022 in Northern Parts of Iran.Mycopathologia · 2024Article
- A Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Emerging Trends in the Use of Topical Antifungal-Corticosteroid Combinations.Journal of fungi (Basel, Switzerland) · 2022Review
- Fungal infections: Pathogenesis, antifungals and alternate treatment approaches.Current research in microbial sciences · 2022Review
- A Review on Antifungal Efficiency of Plant Extracts Entrenched Polysaccharide-Based Nanohydrogels.Nutrients · 2021Review
- The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses.American journal of clinical dermatology · 2021Article
- The Transcriptional Profile ofPathogens (Basel, Switzerland) · 2019Article
- Preparation, Characterisation, and Topical Delivery of Terbinafine.Pharmaceutics · 2019Article
- A 61-year-old man with erythematous forearm papules three months after liver transplantation.Transplant infectious disease : an official journal of the Transplantation Society · 2018Article
- Antifungal activity ofDrug design, development and therapy · 2018Article
- In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinafine hydrochloride.Journal of advanced research · 2016Article
- Antifungal Drug Susceptibility Testing of Dermatophytes: Laboratory Findings to Clinical Implications.Indian dermatology online journalArticle
- Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungal infections, aided by unique pharmacologic and microbiologic profiles. This article reviews mode of action, antimycotic spectrum and disposition profile of terbinafine. It examines the data, accumulated over 15 years, on the comparative efficacy of terbinafine (vs griseofulvin, itraconazole, fluconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.